While several countries have suspended AstraZeneca COVID-19 jab over blood clot fears, Malaysia has decided to continue with its vaccination program as planned. The country will receive the AstraZeneca doses later this month, said the media reports.
Health Minister Datuk Seri Dr Adham Baba said the government was confident in the conditional approval issued by the National Pharmaceutical Regulatory Agency (NPRA) for the vaccine to be used in Malaysia. However, he said, the NPRA would study additional documents on the vaccine’s side effects, which had been widely reported in several countries and led to its suspension. Also Read: Pfizer’s COVID-19 vaccine is 97% effective for symptomatic infections, says latest study
“We are confident in NPRA’s decision to approve the AstraZeneca vaccine. We have taken into account its effectiveness, safety and quality in securing its approval.. We are exercising caution on what was reported (in cases elsewhere). We are taking all necessary precautions and take into account the factors that make an individual unable to be inoculated,” he said.
“We will continue to advise the people on the latest developments and give our assurance that the vaccination programme is a commendable one,” the minister told media. Also Read: US approves Johnson & Johnson’s single-dose COVID-19 vaccine for emergency use
Several countries, including Denmark, Norway, Iceland, Spain and Portugal have temporarily suspended the use of the AstraZeneca shots after European Medicines Agency reported 30 cases of blood clots among vaccine recipients. The World Health Organisation, meanwhile, said that data showed no evidence of a link between the vaccine and blood clots.